Please use this identifier to cite or link to this item:
|Title:||Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept|
|Author:||Ferreiro Iglesias, Aída|
Pérez Pampin, Eva
Cañete Crespillo, Juan D.
Magro Checa, Cesar
Ferrer, Miguel Angel
Pascual Salcedo, Dora
Blanco, Francisco J.
Moreno Ramos, Manuel J.
Manrique Arija, Sara
Ordóñez, María del Carmen
Alegre-Sancho, Juan José
Narváez García, Francisco Javier
Navarro Sarabia, Federico
García Portales, Rosa
Gomez Reino, Juan J.
|Publisher:||Public Library of Science (PLoS)|
|Abstract:||Research in rheumatoid arthritis (RA) is increasingly focused on the discovery of biomarkers that could enable personalized treatments. The genetic biomarkers associated with the response to TNF inhibitors (TNFi) are among the most studied. They include 12 SNPs exhibiting promising results in the three largest genome-wide association studies (GWAS). However, they still require further validation. With this aim, we assessed their association with response to TNFi in a replication study, and a meta-analysis summarizing all non-redundant data. The replication involved 755 patients with RA that were treated for the first time with a biologic drug, which was either infliximab (n = 397), etanercept (n = 155) or adalimumab (n = 203). Their DNA samples were successfully genotyped with a single-base extension multiplex method. Lamentably, none of the 12 SNPs was associated with response to the TNFi in the replication study (p > 0.05). However, a drug-stratified exploratory analysis revealed a significant association of the NUBPL rs2378945 SNP with a poor response to etanercept (B = -0.50, 95% CI = -0.82, -0.17, p = 0.003). In addition, the meta-analysis reinforced the previous association of three SNPs: rs2378945, rs12142623, and rs4651370. In contrast, five of the remaining SNPs were less associated than before, and the other four SNPs were no longer associated with the response to treatment. In summary, our results highlight the complexity of the pharmacogenetics of TNFi in RA showing that it could involve a drug-specific component and clarifying the status of the 12 GWAS-drawn SNPs|
|Note:||Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0213073|
|It is part of:||PLoS One, 2019, vol. 14, num. 2, p. e0213073|
|Appears in Collections:||Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)|
Articles publicats en revistes (Ciències Clíniques)
This item is licensed under a Creative Commons License